pf-07258669
Small moleculeexperimental
Clinical trial activity
4 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Nov 27, 2020 (NCT04628793)
Timeline
2020s
- Jan 1, 2020
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Melanocortin receptor 4ANTAGONIST
MC4R antagonist
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL5095286 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07086664 | Phase 1 | Aug 5, 2025 | Pfizer |
| NCT06706869 | Phase 1 | Jan 2, 2025 | Pfizer |
| NCT05113940 | Phase 1 | Nov 3, 2021 | Pfizer |
| NCT04628793 | Phase 1 | Nov 27, 2020 | Pfizer |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Pfizer | For profit | 4 | 4 | 1 | 2020 |
1 organizations
Page 1 / 1